Search
4-Methoxyamphetamine
go.drugbank.com/drugs/DB01472ExperimentalIllicitSynonyms: D,L-p-methoxyamphetamineJNJ-26489112
go.drugbank.com/drugs/DB15203InvestigationalJNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive
Praliciguat
go.drugbank.com/drugs/DB16300InvestigationalPraliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (Hfpef)).
Capromorelin
go.drugbank.com/drugs/DB15205InvestigationalCapromorelin is under investigation in clinical trial NCT00527046 (Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults).
Mannitol busulfan
go.drugbank.com/drugs/DB12097ApprovedWithdrawnMm has been used in trials studying the treatment of Cocaine Dependence and Diabetes Mellitus, Type 2.
Zifibancimig
go.drugbank.com/drugs/DB19332InvestigationalZifibancimig is under investigation in clinical trial NCT04567303, focusing on participants with neovascular age-related macular degeneration.
Dynorphin
go.drugbank.com/drugs/DB16146InvestigationalDynorphin is under investigation in clinical trial NCT00000244 (Effects of Dynorphin 1-13 on Heroin Addiction - 1).
C-peptide
go.drugbank.com/drugs/DB16187InvestigationalC-peptide is under investigation in clinical trial NCT00278980 (Effect of C-peptide on Diabetic Peripheral Neuropathy).
Lexanersen
go.drugbank.com/drugs/DB17933InvestigationalLexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Synonyms: Dna, d(rgm-(p(s))-sp-rum-rgm-rcm-ram-(p(s))-sp-c-(p(s))-sp-a-(p(s))-sp-c-(p(s))-sp-a-(p(s))-sp-g-(p(s))-sp-t-(p(s))-sp-a-(p(s))-sp-g-(p(r))-sp-a-(p(s))-sp-t-(p(s))-sp-rgm-ram-rgm-rgm-(p(s))-sp-rgm)Evobrutinib
go.drugbank.com/drugs/DB15170InvestigationalEvobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).